Lee S. Schwartzberg MD, FACP
Chief, Medical Oncology and Hematology, Renown Institute for Cancer, and Professor of Clinical Medicine, University of Nevada, Reno, NevadaDr. Lee Schwartzberg is Chief, Medical Oncology and Hematology at the Renown Institute for Cancer and Professor of Clinical Medicine at the University of Nevada, Reno. He completed his hematology/oncology fellowship at Memorial Sloan Kettering Cancer Center and spent 3 decades at West Cancer Center and Research Institute as Medical Director. He was Chief, Division of Hematology/Oncology and Professor of Medicine at the University of Tennessee Health Science Center from 2012 to 2017.
In 2018, he became the founding Chief Medical Officer of OneOncology, a national oncology practice management company and served in that role through 2021. He previously served on the Board of Directors and the Guideline Steering Committee of the National Comprehensive Cancer Network and participated in several guideline committees, including the committee for breast cancer.
Dr. Schwartzberg has published nearly 300 peer-reviewed manuscripts, book chapters, and monographs. He is the founding Editor-in-Chief of the Elsevier website PracticeUpdate Oncology and the founding Editor-in-Chief of the journal Community Oncology. His research interests focus on breast cancer, supportive care, precision medicine, and patient-reported outcomes. Dr. Schwartzberg maintains a clinical practice in breast cancer.
Disclosures
- Consultant: Amgen; Pfizer; Helsinn; Genentech; BMS (Bristol; Myer; Squibb); Myriad; AstraZeneca; Spectrum; Napo
- Advisory boards: Genomic Health Research Funding (Institution): Amgen; DSMB: Bayer
Recent Contributions to PracticeUpdate:
- Metronomic Chemotherapy for Metastatic Breast Cancer: A Meta-Analysis
- Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
- Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
- Association of the Timing of Pregnancy With Survival in Women With Breast Cancer
- Some Survival Benefit With Resection for Breast Cancer Liver Metastases
- HER2-Enriched Subtype as a Predictor of Pathological Complete Response Following Trastuzumab and Lapatinib Without Chemotherapy in Early-Stage HER2-Positive Breast Cancer
- Current Status of Immune Checkpoint Inhibitors for Breast Cancer
- Effect of a Scalp Cooling Device on Alopecia in Women Undergoing Chemotherapy for Breast Cancer
- Effect of a Scalp Cooling Device on Alopecia in Women Undergoing Chemotherapy for Breast Cancer
- Scalp Cooling Device Associated With Less Alopecia After Chemotherapy for Breast Cancer